Compounds > isoproterenol

isoproterenol and ritonavir

isoproterenol has been researched along with ritonavir in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's6 (85.71)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Adler-Wailes, DC; Ahmad, F; Feng, N; Liu, H; Londos, C; Manganiello, V; Yanovski, JA1
Adler-Wailes, DC; Guiney, EL; Wolins, NE; Yanovski, JA1
Banerjee, SK; Bulani, Y; Gupta, P; Kanwal, A; Khatua, TN; Kuncha, M; Putcha, UK; Sojitra, B1

Reviews

1 review(s) available for isoproterenol and ritonavir

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

6 other study(ies) available for isoproterenol and ritonavir

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis.
    The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:6

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3T3 Cells; Adipocytes; Animals; Cell Differentiation; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; HIV Protease Inhibitors; Isoproterenol; Lipolysis; Mice; Ritonavir

2005
Long-term ritonavir exposure increases fatty acid and glycerol recycling in 3T3-L1 adipocytes as compensatory mechanisms for increased triacylglycerol hydrolysis.
    Endocrinology, 2010, Volume: 151, Issue:5

    Topics: 3T3-L1 Cells; Adipocytes; Adrenergic beta-Agonists; Animals; Enzyme Inhibitors; Fatty Acids; Gene Expression; Glycerol; HIV Protease Inhibitors; Humans; Hydrolysis; Immunoblotting; Isoproterenol; Lipase; Lipodystrophy; Mice; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Time Factors; Triazenes; Triglycerides

2010
Cardioprotective effect of ritonavir, an antiviral drug, in isoproterenol induced myocardial necrosis: a new therapeutic implication.
    Journal of translational medicine, 2013, Mar-26, Volume: 11

    Topics: Animals; Antioxidants; Body Weight; Cardiomyopathies; Cardiotonic Agents; Glucose Transporter Type 4; Isoproterenol; Male; Mice; Necrosis; Nitric Oxide; Oxidative Stress; Phlorhizin; Ritonavir; Thiobarbituric Acid Reactive Substances

2013